Why the study?
With the restoration of elite sport, appropriate screening and management pathways considering cardiovascular implications are needed to guide return-to-play decisions for athletes with COVID-19.
Emphasizes the need for tailored cardiovascular screening and management pathways for elite athletes returning to play after COVID-19 infection.
Tailored CV screening may remain prudent before unrestricted RTP in post-COVID athletes; leaves open Long COVID incidence and best protocols.
Curtailing elite sports during the coronavirus disease 2019 (COVID-19) pandemic was necessary to prevent widespread viral transmission. Now that elite sport and international competitions have been largely restored, there is still a need to devise appropriate screening and management pathways for athletes with a history of, or current, COVID-19 infection. These approaches should support the decision-making process of coaches, sports medicine practitioners and the athlete about the suitability to return to training and competition activities. In the absence of longitudinal data sets from athlete populations, the incidence of developing prolonged and debilitating symptoms (i.e., Long COVID) that affects a return to training and competition remains a challenge to sports and exercise scientists, sports medicine practitioners and clinical groups. As the world attempts to adjust toward 'living with COVID-19' the very nature of elite and international sporting competition poses a risk to athlete welfare that must be screened for and managed with bespoke protocols that consider the cardiovascular implications for performance.
No takes yet. Share an insight, caveat, or question.
Faghy et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: